Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOMBOLA: Atezolizumab at ctDNA-positive biochemical relapse after radical cystectomy
2024-510865-41-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of atezolizumab in transitional cell carcinoma of the bladder (TCC) and transitional cell carcinoma (TCC), sponsored by Central Denmark Region. Primary endpoint: Complete response rate after atezolizumab initiated by ctDNA-positive status. Planned start Jun 2024; status: authorised.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-510865-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510865-41-00.